Primary Myelofibrosis

This is a rare blood cancer that affects the bone marrow, the soft tissue inside your bones where blood cells are made. In this condition, the bone marrow gets replaced by scar tissue, which disrupts the production of normal blood cells. This can lead to anemia, fatigue, and an increased risk of infections.

Condition

What people with Primary Myelofibrosis report

Every report comes from a Lived member, sent anonymously.

Have you had Stem Cell Transplant for Primary Myelofibrosis?

NameHow it went

About Primary Myelofibrosis

What It Is

Primary myelofibrosis is a rare, chronic blood cancer in which scar tissue (fibrosis) gradually builds up in the bone marrow, the spongy tissue inside bones where blood cells are made. As the marrow becomes scarred, it can no longer produce enough normal red blood cells, white blood cells and platelets. It belongs to a group of diseases called myeloproliferative neoplasms, in which abnormal blood-forming stem cells grow and behave in ways they should not. Many people have no symptoms at first, and the disease is often found on a routine blood test. Over time, a shortage of red blood cells (anemia) can cause tiredness and shortness of breath, low platelets can lead to easy bruising or bleeding, and low white blood cells can make infections more likely. Because the marrow is failing, the spleen and liver start making blood cells themselves. This often enlarges the spleen, which can cause fullness or discomfort below the ribs on the left side and a feeling of being full after eating only a little. Fevers, drenching night sweats, weight loss and bone pain are also common. It is most often diagnosed between ages 50 and 80. It is called primary when it arises on its own, rather than developing later from two related conditions, polycythemia vera or essential thrombocythemia, which is called secondary myelofibrosis. Doctors also recognize an early, prefibrotic form, which often starts with a high platelet count before much scarring has occurred.

Causes & Risk Factors

Primary myelofibrosis is caused by genetic changes that a blood-forming stem cell acquires during a person's life. These changes are not inherited and are not passed on to children. Most people have a change in one of three genes that help control blood cell growth, known by the abbreviations JAK2, CALR and MPL. Changes in any of these three genes switch on a growth signal inside blood cells that should normally turn on and off. The overactive cells, particularly the large cells that make platelets, release substances that drive scarring in the marrow. Some people have none of these three changes, and researchers are still looking for other causes. The main known risk factor is age. No lifestyle habit or infection has been shown to cause the disease or to trigger it, so having it does not mean someone did something wrong.

How It's Diagnosed

Diagnosis usually starts with a complete blood count (CBC), which measures red cells, white cells and platelets, and a physical exam that checks whether the spleen is enlarged. A blood smear, in which a sample is examined under a microscope, may show red blood cells shaped like teardrops or immature blood cells (blasts) that normally stay in the marrow. These are clues that the marrow is scarred. A bone marrow aspiration and biopsy confirms the diagnosis. After numbing the skin, a doctor uses a hollow needle to remove a small sample of marrow and bone, usually from the hip bone. The sample shows the scarring and the pattern of abnormal cells. Genetic testing of the blood or marrow looks for changes in JAK2, CALR or MPL, and chromosome testing looks for larger changes in the cells' DNA. Finding one of the three gene changes supports the diagnosis, but it is not required. The results are then combined into a risk score. Scoring systems weigh age, symptoms such as fever, night sweats and weight loss, how low the blood counts are, the share of blasts in the blood and the chromosome and gene findings. The result places a person in a risk group from very low to very high. This matters because it is the main guide to whether to watch, treat symptoms or consider a transplant.

Treatment Options

Treatment depends on the risk group and on which problems a person has. People with lower-risk disease and no troublesome symptoms are usually monitored with regular blood counts rather than treated right away, an approach called watchful waiting. The only treatment that can potentially cure primary myelofibrosis is an allogeneic stem cell transplant, which replaces the diseased marrow with blood-forming cells from a donor. It is a demanding treatment, so it is generally considered for people with higher-risk disease who are healthy enough to go through it. For most other people, medicines aim to shrink an enlarged spleen, ease symptoms and manage blood counts. They do not cure the disease. The main group is JAK inhibitors, daily pills that calm the overactive growth signal behind the disease. Ruxolitinib (Jakafi) is the most widely used. Fedratinib (Inrebic) is another option. Pacritinib (Vonjo) is approved for people whose platelet count is very low, below 50,000 per microliter, and momelotinib (Ojjaara) is approved for people who also have anemia and, in studies, helped more people stop needing regular transfusions while also shrinking the spleen. JAK inhibitors can lower blood counts and raise the risk of infection, so blood tests are checked often, especially in the first months. Stopping one suddenly can bring symptoms back quickly, so changes should be made only with the prescriber. Anemia is often treated with red blood cell transfusions. Other medicines may help raise red cell counts, including drugs that stimulate red blood cell production, danazol (a synthetic male hormone), prednisone (a steroid) and immune-modulating drugs such as lenalidomide (Revlimid). Each helps only some people, so the choice depends on the person's other blood counts and health. Hydroxyurea, an oral chemotherapy pill, can help control high blood counts or spleen size. When a spleen stays painful and enlarged despite medicine, surgery to remove it or radiation to it may be options. Clinical trials of newer drugs are also available at many specialist centers.

What to Expect

The course of primary myelofibrosis varies widely. Some people with lower-risk disease stay well for many years with little or no treatment, while people with higher-risk disease face a substantially shorter life expectancy. Over time, blood counts often fall further, transfusion needs can grow, the spleen can enlarge and fatigue, night sweats and weight loss can become harder to manage. In some people the disease changes into acute myeloid leukemia, a fast-growing form of blood cancer. That change, infections and heart and blood vessel problems are the most common serious complications. Care is ongoing. Regular appointments track blood counts, spleen size and symptoms, and the risk score may be recalculated as things change. Many people are cared for by a hematologist (a blood specialist), and it is often useful to see a center experienced in myelofibrosis early, even before a transplant is needed, so the option can be weighed in good time.

When to Seek Help

See a doctor if you have ongoing tiredness, fullness or discomfort below the left ribs, feeling full after small meals, drenching night sweats or unexplained weight loss, or if a routine blood test shows abnormal counts. If you have myelofibrosis, contact your care team promptly for a fever or other signs of infection, especially if you take a JAK inhibitor or your white cell count is low. Also call promptly about new tiny red spots on the skin, easier bruising or a rapid increase in tiredness or breathlessness, since these can mean your counts have dropped. Bleeding that will not stop with pressure, vomiting blood, or black or bloody stools needs emergency care right away.

Questions to Ask Your Doctor

  1. 1.What is my risk group, and which of my test results put me there?
  2. 2.Is watchful waiting reasonable for me now, and what changes would make us start treatment?
  3. 3.If I need a JAK inhibitor, which one fits my blood counts and symptoms, and how will we tell whether it is working?
  4. 4.Should I be evaluated at a transplant center now, even if I do not need a transplant yet?
  5. 5.How will we manage my anemia and fatigue, and are there clinical trials I should consider?

Last reviewed • Oct 2026

Educational content, not medical advice.